Cullinan Therapeutics (CGEM) Cash & Equivalents (2020 - 2026)

Cullinan Therapeutics' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $351.9 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 15.83% year-over-year to $351.9 million in Q1 2026; TTM through Mar 2026 was $351.9 million, a 15.83% increase from a year earlier, with the FY2025 full-year figure at $88.3 million, up 6.42% from the prior year.
• Cash & Equivalents grew to $351.9 million in Q1 2026 per CGEM's latest filing, from $88.3 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $611.0 million in Q2 2022 and bottomed at $72.8 million in Q2 2025.
• The 5-year median for Cash & Equivalents is $242.7 million (2022), against an average of $264.9 million.
• Across the five-year window, Cash & Equivalents soared 394.06% in 2022 and tumbled 76.61% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $156.2 million in 2022, then plunged by 36.96% to $98.4 million in 2023, then declined by 15.67% to $83.0 million in 2024, then advanced by 6.42% to $88.3 million in 2025, then surged by 298.38% to $351.9 million in 2026.
• Per Business Quant, the three latest CGEM Cash & Equivalents figures stand at $351.9 million (Q1 2026), $88.3 million (Q4 2025), and $332.6 million (Q3 2025).